247 related articles for article (PubMed ID: 32212784)
1. The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
El-Daly UM; Saber MM; Abdellateif MS; Nassar HR; Namour AE; Ismail YM; Zekri AN
Asian Pac J Cancer Prev; 2020 Mar; 21(3):599-609. PubMed ID: 32212784
[TBL] [Abstract][Full Text] [Related]
2. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Tsai IT; Wang CP; Yu TH; Lu YC; Lin CW; Lu LF; Wu CC; Chung FM; Lee YJ; Hung WC; Hsu CC
Cytokine; 2017 Feb; 90():54-59. PubMed ID: 27770715
[TBL] [Abstract][Full Text] [Related]
3. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan.
Chen CL; Yang WS; Yang HI; Chen CF; You SL; Wang LY; Lu SN; Liu CJ; Kao JH; Chen PJ; Chen DS; Chen CJ
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1659-71. PubMed ID: 24895413
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
5. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract][Full Text] [Related]
6. Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Pazgan-Simon M; Kukla M; Zuwała-Jagiełło J; Derra A; Bator M; Menżyk T; Lekstan A; Grzebyk E; Simon K
PLoS One; 2020; 15(1):e0227459. PubMed ID: 31935230
[TBL] [Abstract][Full Text] [Related]
7. Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report.
Cantarini L; Brucato A; Simonini G; Imazio M; Cumetti D; Cimaz R; Bacarelli MR; Muscari I; Vitale A; Lucherini OM; Galeazzi M; Fioravanti A
Clin Exp Rheumatol; 2013; 31(2):207-12. PubMed ID: 23137677
[TBL] [Abstract][Full Text] [Related]
8. Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.
Shen J; Yeh CC; Wang Q; Gurvich I; Siegel AB; Santella RM
Anticancer Res; 2016 Oct; 36(10):5307-5314. PubMed ID: 27798893
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis.
Nkontchou G; Bastard JP; Ziol M; Aout M; Cosson E; Ganne-Carrie N; Grando-Lemaire V; Roulot D; Capeau J; Trinchet JC; Vicaut E; Beaugrand M
J Hepatol; 2010 Nov; 53(5):827-33. PubMed ID: 20728234
[TBL] [Abstract][Full Text] [Related]
10. Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis.
Bastard JP; Fellahi S; Audureau É; Layese R; Roudot-Thoraval F; Cagnot C; Mahuas-Bourcier V; Sutton A; Ziol M; Capeau J; Nahon P;
Eur Cytokine Netw; 2018 Sep; 29(3):112-120. PubMed ID: 30547888
[TBL] [Abstract][Full Text] [Related]
11. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Assiri AM; Kamel HF; Hassanien MF
Dis Markers; 2015; 2015():253519. PubMed ID: 25838618
[TBL] [Abstract][Full Text] [Related]
12. Splanchnic concentrations and postprandial release of visceral adipokines.
Wiest R; Moleda L; Farkas S; Scherer M; Kopp A; Wönckhaus U; Büchler C; Schölmerich J; Schäffler A
Metabolism; 2010 May; 59(5):664-70. PubMed ID: 19913846
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
14. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
15. The role of serum visfatin and vaspin in hepatocellular carcinoma in hepatitis C-related liver cirrhosis.
Abdelhamed W; Morsy KH; Hefny HM; Abudeif A
Clin Exp Hepatol; 2023 Sep; 9(3):210-220. PubMed ID: 37790689
[TBL] [Abstract][Full Text] [Related]
16. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
Menopause; 2011 Nov; 18(11):1198-204. PubMed ID: 21712732
[TBL] [Abstract][Full Text] [Related]
18. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.
Hsu CS; Liu WL; Chao YC; Lin HH; Tseng TC; Wang CC; Chen DS; Kao JH
Hepatol Int; 2015 Apr; 9(2):231-42. PubMed ID: 25788201
[TBL] [Abstract][Full Text] [Related]
19. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients.
Sadik NA; Ahmed A; Ahmed S
Hum Exp Toxicol; 2012 Apr; 31(4):311-21. PubMed ID: 22249387
[TBL] [Abstract][Full Text] [Related]
20. Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
Cantarini L; Obici L; Simonini G; Cimaz R; Bacarelli MR; Merlini G; Vitale A; Lucherini OM; Brizi MG; Galeazzi M; Fioravanti A
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S108-14. PubMed ID: 22935190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
